Company news

Hikma Pharmaceuticals PLC news in 2025

Hikma Pharmaceuticals PLC's news releases, calls and decks from 2025, newest first.

View company

Hikma announces CEO change and Board appointment

December 15, 2025

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

December 8, 2025

Holding(s) in Company

November 11, 2025

November Trading Statement

November 6, 2025

Block listing Interim Review

October 1, 2025

Half-year Report

August 7, 2025

Publication of Offering Circular

July 7, 2025

Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US

July 2, 2025

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

June 28, 2025

Fitch upgrades Hikma to ‘BBB’

May 29, 2025

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

May 27, 2025

Medium-term Group guidance ahead of US site visit

May 15, 2025

S&P upgrades Hikma to ‘BBB’

May 8, 2025

Settlement agreement for Xyrem® US lawsuits

May 8, 2025

Result of AGM

April 24, 2025

Trading Statement

April 24, 2025

Hikma acquires Novugen's FDA-approved ANDA for trametinib

April 17, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

March 20, 2025

Final Results

February 26, 2025

Calls in 2025

Decks in 2025